ah 6809 has been researched along with thromboxane b2 in 1 studies
| Studies (ah 6809) | Trials (ah 6809) | Recent Studies (post-2010) (ah 6809) | Studies (thromboxane b2) | Trials (thromboxane b2) | Recent Studies (post-2010) (thromboxane b2) |
|---|---|---|---|---|---|
| 163 | 1 | 49 | 7,483 | 715 | 485 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bessard, G; Chavanon, O; Cracowski, JL; Devillier, P; Hunt, M; Souvignet, C; Stanke-Labesque, F | 1 |
1 other study(ies) available for ah 6809 and thromboxane b2
| Article | Year |
|---|---|
Human internal mammary artery contraction by isoprostaglandin f(2alpha) type-III [8-iso-prostaglandin F(2alpha)].
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adult; Aged; Benzoquinones; Biphenyl Compounds; Dinoprost; Dose-Response Relationship, Drug; F2-Isoprostanes; Female; Flavanones; Flavonoids; Heptanoic Acids; Humans; In Vitro Techniques; Leukotrienes; Lipoxygenase Inhibitors; Male; Mammary Arteries; Middle Aged; Prostaglandin Antagonists; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP1 Subtype; Receptors, Thromboxane; Thromboxane B2; Vasoconstriction; Vasoconstrictor Agents; Xanthenes; Xanthones | 2000 |